食品与发酵工业 >

2021 , Vol. 47 >Issue 21: 102 - 108

DOI: https://doi.org/10.13995/j.cnki.11-1802/ts.026312

研究报告

共轭亚油酸甘油酯及其微囊乳液对高脂饮食诱导的大鼠非酒精性脂肪肝的缓解作用

  • 文瑾 ,
  • 范超 ,
  • 夏俪宁 ,
  • 石超 ,
  • 吴文忠
展开
  • (大连医诺生物股份有限公司,辽宁 大连,116600)
硕士,药师(吴文忠研究员为通讯作者,E-mail:wu@innobio.cn)

收稿日期: 2020-11-29

  修回日期: 2021-01-25

  网络出版日期: 2021-11-30

收起

Amelioration effects of conjugated linoleic acid glyceride and microencapsulated emulsion on high-fat diet induced non-alcoholic fatty liver disease in rats

  • WEN Jin ,
  • FAN Chao ,
  • XIA Lining ,
  • SHI Chao ,
  • WU Wenzhong
Expand
  • (INNOBIO, Dalian 116600, China)

Received date: 2020-11-29

  Revised date: 2021-01-25

  Online published: 2021-11-30

Fold

摘要

为研究共轭亚油酸甘油酯(conjugated linoleic acid glyceride, CLA-TG)及其微囊化乳液对高脂饮食诱导的非酒精性脂肪肝(non-alcoholic fatty liver disease NAFLD)相关指标的影响,采用6周高脂饮食建立大鼠NAFLD模型,通过CLA-TG或微囊化CLA-TG干预,记录体重、摄食量,造模结束后收集肝脏及血清,检测血清学指标谷丙转氨酶(alanine aminotransferase,ALT)、谷草转氨酶(aspartate aminotransferase,AST)、总胆固醇(total cholesterol, TC)、低密度脂蛋白胆固醇(low-density lipoprotein cholesterol, LDL-C)、高密度脂蛋白胆固醇(high-density lipoprotein cholesterol, HDL-C)及甘油三酯(triglycerides, TG)水平;检测肝脏TG含量及油红O染色观察脂滴积聚情况。结果表明,各组大鼠实验周期内摄食量无较大差异。与空白对照组相比,模型组大鼠体重、血脂水平显著升高,肝脏出现明显的肝脂肪变,表现为显著的TG累积及脂滴积聚。CLA-TG及微囊化CLA-TG的摄入使上述指标均明显缓解,且微囊化CLA-TG组改善肝损伤效果更为显著。CLA-TG的摄入可对NAFLD起到显著的缓解作用,且微囊化后缓解作用进一步增强。

关键词： 非酒精性脂肪肝; 共轭亚油酸甘油酯; 微囊; 肥胖; 脂质代谢

本文引用格式

文瑾 , 范超 , 夏俪宁 , 石超 , 吴文忠 . 共轭亚油酸甘油酯及其微囊乳液对高脂饮食诱导的大鼠非酒精性脂肪肝的缓解作用[J]. 食品与发酵工业, 2021 , 47(21) : 102 -108 . DOI: 10.13995/j.cnki.11-1802/ts.026312

Abstract

This study aimed to investigate the effects of conjugated linoleic acid glyceride oil (CLA-TG) and microencapsulated CLA-TG emulsion on high-fat diet induced non-alcoholic fatty liver disease in rats.Male Sprague-Dawley rats were fed with high-fat diet for 6 weeks to establish the non-alcoholic fatty liver disease model.At the same time, the intervention groups were fed with CLA-TG oil and microencapsulated CLA-TG emulsion. Body weight and food intake were recorded.After 6 weeks treatment, the liver and blood were collected to exam the liver function indicators alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) in serum and triglycerides (TG) in liver. And oil-red O staining was used to observe the lipid accumulation of liver tissue. Results showed that the food intake of all groups showed no significant difference. Compared with the control group, the body weight in the model group increased significantly (P<0.01). The levels of serum ALT、AST、TC、TG、LDL-C were also significantly elevated (P<0.01) and HDL-C were significantly decreased (P<0.05). Sever steatosis were observed in the liver tissue which showed excessive TG and lipid accumulation (P<0.01).Compared with the model group, body weight, serum blood lipids levels, liver TG and lipid accumulation were significantly lower in CLA-TG group and microencapsulated CLA-TG emulsion groups (P<0.05). Moreover, the microencapsulated CLA-TG emulsion group showed better amelioration effects. The ingestion of CLA-TG can improve non-alcoholic fatty liver disease in rats and microencapsulated CLA-TG emulsion can further enhance the protective effects.

Key words： non-alcoholic fatty liver disease; conjugated linoleic acid glyceride (CLA-TG); microcapsule; obesity; lipid metabolism

参考文献

[1] PARRY S A,HODSON L.Influence of dietary macronutrients on liver fat accumulation and metabolism[J].Journal of Investigative Medicine,2017,65(8):1 102-1 115.
[2] ANGULO P.Nonalcoholic fatty liver disease//Encyclopedia of Gastroenterology[M].Amsterdam:Elsevier,2004:733-736.
[3] TILG H,MOSCHEN A R,RODEN M.NAFLD and diabetes mellitus[J].Nature Reviews Gastroenterology & Hepatology,2017,14(1):32-42.
[4] KOBA K,YANAGITA T.Health benefits of conjugated linoleic acid (CLA)[J].Obesity Research & Clinical Practice,2014,8(6):e525-e532.
[5] GAJDZIOK J,VRANÍKOVÁ B.Enhancing of drug bioavailability using liquisolid system formulation[J].Ceska a Slovenska Farmacie,2015,64(3):55-66.
[6] SUN R M,KANG X H,ZHAO Y,et al.Sirtuin 3-mediated deacetylation of acyl-CoA synthetase family member 3 by protocatechuic acid attenuates non-alcoholic fatty liver disease[J].British Journal of Pharmacology,2020,177(18):4 166-4 180.
[7] SHAN W,GAO L,ZENG W,et al.Activation of the SIRT1/p66 shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease[J].Cell Death & Disease,2015,6(7):e1833.
[8] WEN J,XU B,SUN Y C,et al.Paeoniflorin protects against intestinal ischemia/reperfusion by activating LKB1/AMPK and promoting autophagy[J].Pharmacological Research,2019,146:104308.
[9] SHI X,SUN R M,ZHAO Y,et al.Promotion of autophagosome-lysosome fusion via salvianolic acid A-mediated SIRT1 up-regulation ameliorates alcoholic liver disease[J].RSC Advances,2018,8(36):20 411-20 422.
[10] RIVA G,VILLANOVA M,CIMA L,et al.Oil red O is a useful tool to assess donor liver steatosis on frozen sections during transplantation[J].Transplantation Proceedings,2018,50(10):3 539-3 543.
[11] 钟晓怡, 林云,郭艳,等.高脂小鼠脂肪肝组织油红O特殊染色的应用[J].上海预防医学,2018,30(10):873-877.
ZHONG X Y,LIN Y,GUO Y,et al.Oil-red O special staining techniques applied in fatty liver tissue of hyperlipidemic mouse[J].Shanghai Journal of Preventive Medicine,2018,30(10):873-877.
[12] POLYZOS S A,KOUNTOURAS J,MANTZOROS C S.Obesity and nonalcoholic fatty liver disease:From pathophysiology to therapeutics[J].Metabolism,2019,92:82-97.
[13] 张配配, 李景贤,李蒙丽,等.番茄红素对非酒精性脂肪肝大鼠糖脂代谢及炎症水平的影响[J].卫生研究,2020,49(2):254-258;271.
ZHANG P P,LI J X,LI M L,et al.Effects of lycopene on metabolism of glycolipid and inflammation in non-alcoholic fatty liver disease rats[J].Journal of Hygiene Research,2020,49(2):254-258;271.
[14] MATO J M,ALONSO C,NOUREDDIN M,et al.Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease[J].World Journal of Gastroenterology,2019,25(24):3 009-3 020.
[15] PERUMPAIL B J,KHAN M A,YOO E R,et al.Clinical epidemiology and disease burden of nonalcoholic fatty liver disease[J].World Journal of Gastroenterology,2017,23(47):8 263-8 276.
[16] CHEN S C,LIN Y H,HUANG H P,et al.Effect of conjugated linoleic acid supplementation on weight loss and body fat composition in a Chinese population[J].Nutrition,2012,28(5):559-565.
[17] YANG J M,SUN Y,WANG M,et al.Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease[J].World Journal of Gastroenterology,2019,25(34):5 105-5 119.
[18] LEHNEN T E,DA SILVA M R,CAMACHO A,et al.A review on effects of conjugated linoleic fatty acid (CLA) upon body composition and energetic metabolism[J].Journal of the International Society of Sports Nutrition,2015,12:36.
[19] MASLAK E,BUCZEK E,SZUMNY A,et al.Individual CLA isomers,c9t11 and t10c12,prevent excess liver glycogen storage and inhibit lipogenic genes expression induced by high-fructose diet in rats[J].Biomed Research International,2015,2015:535 982.
[20] 祝彤彤, 张辉珍,王晓滨,等.共轭亚油酸甘油酯对大鼠血清脂肪酸组成影响的研究[J].现代生物医学进展,2016,16(15):2 842-2 846.
ZHU T T,ZHANG H Z,WANG X B,et al.Effects of conjugated linoleic acid glycerides on the composition of serum fatty acid in rats[J].Progress in Modern Biomedicine,2016,16(15):2 842-2 846.
[21] NEUBAUER M P,POEHLMANN M,FERY A.Microcapsule mechanics:From stability to function[J].Advances in Colloid and Interface Science,2014,207:65-80.
[22] LÓPEZ-LLUCH G,DEL POZO-CRUZ J,SÁNCHEZ-CUESTA A,et al.Bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization[J].Nutrition,2019,57:133-140.
[23] 刘明, 徐维锋,张显仁,等.共轭亚油酸甘油酯的储存稳定性研究[J].中国油脂,2012,37(10):50-52.
LIU M,XU W F,ZHANG X R,et al.Storage stability of conjugated linoleic acid glyceride[J].China Oils and Fats,2012,37(10):50-52.
[24] YOUNOSSI Z,ANSTEE Q M,MARIETTI M,et al.Global burden of NAFLD and NASH:Trends,predictions,risk factors and prevention[J].Nature Reviews Gastroenterology & Hepatology,2018,15(1):11-20.
[25] POLYZOS S A,KOUNTOURAS J,MANTZOROS C S.Adipose tissue,obesity and non-alcoholic fatty liver disease[J].Minerva Endocrinologica,2017,42(2):92-108.
[26] ALEXANDER M,LOOMIS A K,VAN DER LEI J,et al.Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD:Real-world study of 18 million patients in four European cohorts[J].BMC Medicine,2019,17(1):95.
[27] MA M J,DUAN R,ZHONG H,et al.The crosstalk between fat homeostasis and liver regional immunity in NAFLD[J].Journal of Immunology Research,2019,2019:3954890.
[28] BYRNE C D,TARGHER G.NAFLD:A multisystem disease[J].Journal of Hepatology,2015,62(1):S47-S64.
[29] RINELLA M E,SANYAL A J.Management of NAFLD:A stage-based approach[J].Nature Reviews Gastroenterology & Hepatology,2016,13(4):196-205.
[29] RINELLA M E,SANYAL A J.Management of NAFLD:A stage-based approach[J].Nature Reviews.Gastroenterology & Hepatology,2016,13(4):196-205.
Options
文章导航

/

〈 〉

技术支持：北京玛格泰克科技发展有限公司